Shareholder Tools

Press Releases

Press Releases
Date Title and Summary View
Nov 5, 2014 Folate-targeted EC1456 with Potent Tubulysin Payload Now at Higher Phase 1 Dose Level than Vintafolide Conference Call Today at 4:30 p.m. EST WEST LAFAYETTE, Ind., Nov. 5, 2014 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for pe...
Nov 4, 2014 WEST LAFAYETTE, Ind., Nov. 4, 2014 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that Mike Sherman, chief financial and operating officer of Endocyte, will present at the 2014 Credit Suisse Healthcare Con...
Oct 29, 2014 WEST LAFAYETTE, Ind., Oct. 29, 2014 (GLOBE NEWSWIRE) -- Endocyte, Inc., (Nasdaq:ECYT) announced today that the company will host a conference call on Wednesday, Nov. 5, at 4:30 p.m. EST to discuss its third quarter 2014 financial results and provide an operational update. Investors and the general public are invited to listen to a live webc...
Sep 27, 2014 - Data Presented Today as Late-Breaker at European Society for Medical Oncology (ESMO) 2014 Congress in Madrid - - Interim Update of Overall Survival Analysis Shows 30 Percent Reduction of Risk of Death in Pre-Defined Adenocarcinoma Patient Subgroup - - Conference Call/Webcast at 8:30 a.m. EDT Monday, Sept. 29 - WEST LAFAYET...
Sep 22, 2014 WEST LAFAYETTE, Ind., Sept. 22, 2014 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that an oral presentation will be presented at the European Society for Medical Oncology (ESMO) Conference on Saturday, S...
Aug 27, 2014 WEST LAFAYETTE, Ind., Aug. 27, 2014 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that the company's management team will present at the Baird 2014 Health Care Conference on Wednesday, Sept. 3, at 2:20 p....
Aug 14, 2014 WEST LAFAYETTE, Ind., Aug. 14, 2014 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that the Company's scientific management team has been selected by the American Chemical Society as the recipient of the 2...
Aug 7, 2014 WEST LAFAYETTE, Ind., Aug. 7, 2014 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that three posters will be presented by Endocyte scientists at the 248th American Chemical Society (ACS) National Meeting &...
Aug 5, 2014 WEST LAFAYETTE, Ind., Aug. 5, 2014 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that the company's management team will present at the Wedbush 2014 Life Sciences Management Access Conference on Tuesday, ...
Jul 29, 2014 - EC1456 Targeting Potent Tubulysin Payload to Advance in Phase 1 to Dose Similar to Vintafolide - - Conference Call Today at 4:30 p.m. EDT - WEST LAFAYETTE, Ind., July 29, 2014 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for p...
Jul 22, 2014 WEST LAFAYETTE, Ind., July 22, 2014 (GLOBE NEWSWIRE) -- Endocyte, Inc., (Nasdaq:ECYT) announced today that the company will host a conference call on Tuesday, July 29, at 4:30 p.m. EDT to discuss its second quarter 2014 financial results and provide an operational update. Investors and the general public are invited to listen to a live webc...
Jun 17, 2014 WEST LAFAYETTE, Ind., June 17, 2014 (GLOBE NEWSWIRE) -- Endocyte, Inc., (Nasdaq:ECYT) today announced that it has regained the worldwide rights to vintafolide in all indications from Merck, known as MSD outside the United States and Canada. Following a comprehensive portfolio assessment, Merck, through a subsidiary, has decided that it will no long...
May 19, 2014 WHITEHOUSE STATION, N.J. & WEST LAFAYETTE, Ind.--(BUSINESS WIRE)-- Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Endocyte, Inc. (NASDAQ:ECYT), today announced the withdrawal of conditional marketing authorization applications (CMA) from the European Medicines Agency (EMA) for vintafolid...
May 19, 2014 WEST LAFAYETTE, Ind., May 19, 2014 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT) a biopharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy in cancer and other serious diseases, today announced that two poster presentations featuring Endocyte's SMDC E...
May 2, 2014 - Independent DSMB Recommends to Stop Phase 3 PROCEED Trial for Futility Following Interim Analysis - - Endocyte Initiates Phase 1 Trial of PSMA-Targeted Tubulysin SMDC (EC1169) in Prostate Cancer Following FDA Acceptance of IND - - Conference Call Today at 8:30 a.m. EDT - WEST LAFAYETTE, Ind., May 2, 2014 (GLOBE NEWSWIRE) ...
May 2, 2014 WHITEHOUSE STATION, N.J. & WEST LAFAYETTE, Ind., May 2, 2014 – Merck, known as MSD outside the United States and Canada (NYSE: MRK), and Endocyte, Inc. (NASDAQ: ECYT), today announced that the Data Safety Monitoring Board (DSMB) of the PROCEED trial has completed a pre specified, interim futility analysis and the DSMB recommended that the t...
May 1, 2014 WEST LAFAYETTE, Ind., May 1, 2014 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that the company has rescheduled the call of its first quarter 2014 financial results and business update to Friday, May 2, ...
Apr 24, 2014 WEST LAFAYETTE, Ind., April 24, 2014 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy in cancer and other serious diseases, today announced that the company will host a conference call on Thursd...
Apr 4, 2014 WEST LAFAYETTE, Ind., April 4, 2014 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT) a biopharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy in cancer and other serious diseases, today announced that three posters will be presented by Endocyte scienti...
Apr 2, 2014 WEST LAFAYETTE, Ind., April 2, 2014 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT) announced today the closing of its previously announced underwritten public offering of 5,175,000 shares of its common stock at a price to the public of $21.00 per share, which includes the exercise in full by the underwriters of their option to purchase 675,000 ad...
Mar 27, 2014 WEST LAFAYETTE, Ind., March 27, 2014 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT) announced the pricing of an underwritten public offering of 4,500,000 shares of its common stock at a price to the public of $21.00 per share. The gross proceeds to Endocyte from this offering, before deducting underwriting discounts and commissions and other offe...
Mar 25, 2014 WEST LAFAYETTE, Ind., March 25, 2014 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT) announced today that it is offering to sell 4.5 million shares of its common stock in an underwritten public offering. The company expects to grant the underwriters a 30-day option to purchase up to an additional 675,000 shares of common stock. The company...
Mar 21, 2014 WEST LAFAYETTE, Ind., March 21, 2014 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT) today announced results from the Phase 2b TARGET trial, which showed that the study met the primary endpoint for the combination of vintafolide (EC145/MK-8109) and docetaxel in folate receptor (FR)-positive recurrent non-small cell lung cancer (NSCLC) patients. As...
Mar 21, 2014 WHITEHOUSE STATION, N.J. & WEST LAFAYETTE, Ind.--(BUSINESS WIRE)-- Merck and Endocyte Announce European CHMP Positive Opinions for VYNFINIT® (vintafolide) and Companion Imaging Agents FOLCEPRI® (etarfolatide) and NEOCEPRI® (Intravenous (IV) folic acid) in Patients with Platinum-...
Feb 25, 2014 WEST LAFAYETTE, Ind., Feb. 25, 2014 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT) a biopharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy in cancer and other serious diseases, today announced that the company's management team will present at the f...
Feb 24, 2014 - Committee for Medicinal Products for Human Use (CHMP) Opinion on Pending EU Marketing Authorization Applications for Vintafolide and Etarfolatide Expected in March Followed by Potential EU Launch - - Key Data Readouts from TARGET Phase 2b Non-Small Cell Lung Cancer (NSCLC) Trial and PROCEED Phase 3 Trial in Platinum-Resistant Ovarian Ca...
Feb 17, 2014 WEST LAFAYETTE, Ind., Feb. 17, 2014 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy in cancer and other serious diseases, today announced that the company will host a conference call on Monday,...
Feb 6, 2014 WEST LAFAYETTE, Ind., Feb. 6, 2014 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT) a biopharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy in cancer and other serious diseases, today announced that the company's management team will present at the fo...
Jan 24, 2014 WEST LAFAYETTE, Ind., Jan. 24, 2014 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy in cancer and other serious diseases, today provided an update regarding the review of the European Medicines...
Dec 16, 2013 WEST LAFAYETTE, Ind., Dec. 16, 2013 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy in cancer and other serious diseases, today announced preclinical data suggesting the company's folate recept...
Dec 12, 2013 WEST LAFAYETTE, Ind., Dec. 12, 2013 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company and leader in targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy in cancer and other serious diseases, today announced that it has dosed the first patient in its Phase 1 clinical trial ...
Nov 26, 2013 WEST LAFAYETTE, Ind., Nov. 26, 2013 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy in cancer and other serious diseases, today announced that Ron Ellis, Endocyte's president and CEO, will pres...
Nov 7, 2013 WEST LAFAYETTE, Ind., Nov. 7, 2013 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy in cancer and other serious diseases, today announced that Colin Goddard, Ph.D. has joined Endocyte's board of...
Nov 6, 2013 WEST LAFAYETTE, Ind., Nov. 6, 2013 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy in cancer and other serious diseases, today announced that Ron Ellis, president and CEO of Endocyte, will pres...
Nov 5, 2013 WEST LAFAYETTE, Ind., Nov. 5, 2013 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy in cancer and other serious diseases, today announced financial results for the third quarter ending Sept. 30,...
Oct 23, 2013 WEST LAFAYETTE, Ind., Oct. 23, 2013 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy in cancer and other serious diseases, today announced that the company will host a conference call on Tuesday...
Oct 14, 2013 Merck and Endocyte's Phase III PROCEED pivotal trial of vintafolide in ovarian cancer ongoing WHITEHOUSE STATION N.J., & WEST LAFAYETTE, Ind.--(BUSINESS WIRE)-- Merck, known as MSD outside the United States and Canada, (NYSE: MRK) and Endocyte, Inc. (NASDAQ: ECYT) today announced the online ...
Oct 11, 2013 - DSMB Recommendations Following Interim Futility Analysis -  - DSMB Recommends an Amendment to Informed Consent Given that the Vintafolide Monotherapy Arm is Unlikely to be Declared Superior to Docetaxel, Patients have Option to Continue Vintafolide Monotherapy - - Top-Line Results for TARGET Trial Expected in Early 2014 - ...
Sep 9, 2013 WEST LAFAYETTE, Ind., Sept. 9, 2013 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy in cancer and other serious diseases, today announced that three posters featuring Endocyte's platform t...
Sep 5, 2013 WEST LAFAYETTE, Ind. and TOKYO, Sept. 5, 2013 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq: ECYT), a biopharmaceutical company and leader in targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy in cancer and other serious diseases, and Nihon Medi-Physics (NMP), a market leader in the development, ...
Aug 27, 2013 WEST LAFAYETTE, Ind., Aug. 27, 2013 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy in cancer and other serious diseases, today announced that the company's management team will present at...
Aug 6, 2013 WEST LAFAYETTE, Ind., Aug. 6, 2013 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy in cancer and other serious diseases, today announced the company's management team will present at the W...
Aug 1, 2013 - Company Completes Enrollment in Phase 2b TARGET Trial in Non-Small Cell Lung Cancer Ahead of Schedule - - Conference Call Today at 4:30 p.m. EDT - WEST LAFAYETTE, Ind., Aug. 1, 2013 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDC...
Jul 18, 2013 WEST LAFAYETTE, Ind., July 18, 2013 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy in cancer and other serious diseases, today announced that the company will host a conference call on Th...
May 30, 2013 WEST LAFAYETTE, Ind., May 30, 2013 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy in cancer and other serious diseases, today announced that the company's investigational cancer candidate, vintafolide ...
May 29, 2013 WEST LAFAYETTE, Ind., May 29, 2013 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy in cancer and other serious diseases, today announced that Mike Sherman, Endocyte's chief financial officer, will prese...
May 7, 2013 WEST LAFAYETTE, Ind., May 7, 2013 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy in cancer and other serious diseases, today announced that Scot L. Harper, Ph.D., has been appointed as vice president o...
May 2, 2013 Preparing for Potential Commercialization in Europe and Expanding SMDC Pipeline Conference call today at 4:30 p.m. EDT WEST LAFAYETTE, Ind., May 2, 2013 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for person...
Apr 25, 2013 Etarfolatide Differentiates Inflammatory from Non-Inflammatory Disease States in Osteoarthritis Patients Data Presented at the OARSI 2013 World Congress on Osteoarthritis PHILADELPHIA, April 25, 2013 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDC...
Apr 22, 2013 WEST LAFAYETTE, Ind., April 22, 2013 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy in cancer and other serious diseases, today announced that it will hold its 2013 Annual Meeting of Stockholders on We...
Apr 18, 2013 WEST LAFAYETTE, Ind., April 18, 2013 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy in cancer and other serious diseases, today announced that the company will host a conference call on Thursday, May 2...
Apr 3, 2013 WEST LAFAYETTE, Ind., April 3, 2013 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy in cancer and other serious diseases, today announced that four poster presentations will be presented by Endocyte sci...
Apr 1, 2013 WEST LAFAYETTE, Ind., April 1, 2013 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy in cancer and other serious diseases, today announced that Ron Ellis, president and CEO of Endocyte, will present at t...
Mar 18, 2013 WEST LAFAYETTE, Ind., March 18, 2013 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy in cancer and other serious diseases, today announced the company's management team will host an Investor and Analyst...
Mar 1, 2013 Patients With 100 Percent Folate Receptor-Positive Tumor Lesions Experienced Substantial Progression-Free Survival When Treated With Vintafolide New Data Presented at AACR-SNMMI Joint Conference on State-of-the-Art Molecular Imaging in Cancer Biology and Therapy SAN DIEGO, March 1, 2013 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECY...
Feb 26, 2013 WEST LAFAYETTE, Ind., Feb. 26, 2013 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy in cancer and other serious diseases, today announced that the company's management team will present at the following...
Feb 25, 2013 - Endocyte and Merck Expand Vintafolide Development - - EMA Approval Decision for Vintafolide Expected by Year-End 2013 - - Conference call today at 4:30 p.m. EST - WEST LAFAYETTE, Ind., Feb. 25, 2013 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conju...
Feb 7, 2013 WEST LAFAYETTE, Ind., Feb. 7, 2013 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy in cancer and other serious diseases, today announced that the company's management team will present at the following ...
Feb 6, 2013 WEST LAFAYETTE, Ind., Feb. 6, 2013 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, today announced that the company will host a conference call on Monday, Feb. 25, at 4:30 p.m. EST to discuss its fourt...
Jan 29, 2013 Company Expects to File IND for Therapeutic Agent in 2013 Human Study of Companion Imaging Agent EC0652 Demonstrates Safety and Binding Specificity WEST LAFAYETTE, Ind., Jan. 29, 2013 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion...
Jan 8, 2013 WEST LAFAYETTE, Ind., Jan. 8, 2013 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy in cancer and other serious diseases, today announced Lesley Russell, M.B.Ch.B., has joined the Endocyte board of direc...
Nov 27, 2012 Novel personalized treatment approach targets folate receptors on cancer cells WHITEHOUSE STATION, N.J. & WEST LAFAYETTE, Ind.--(BUSINESS WIRE)-- Merck, known as MSD outside the United States and Canada (NYSE: MRK), and Endocyte Inc. (NASDAQ: ECYT), today announced that the European ...
Nov 6, 2012 WEST LAFAYETTE, Ind., Nov. 6, 2012 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy in cancer and other serious diseases, today announced that management will present at the following upcoming conference...
Nov 1, 2012 - MAA Filing Process for Vintafolide and Etarfolatide on Schedule for Completion by Year-End 2012 - - Conference call today at 4:30 EDT - WEST LAFAYETTE, Ind., Nov. 1, 2012 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging d...
Oct 25, 2012 WEST LAFAYETTE, Ind., Oct. 25, 2012 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, today announced that the company will host a conference call on Thursday, Nov. 1, at 4:30 p.m. EDT, to discuss its th...
Oct 12, 2012 - Results Show 72 Percent of Adenocarcinomas and 51 Percent of Squamous Cell Carcinoma of the Lung Express Folate Receptor - - Data Published in Archives of Pathology & Laboratory Medicine - WEST LAFAYETTE, Ind., Oct. 12, 2012 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small mol...
Sep 27, 2012 WEST LAFAYETTE, Ind., Sept. 27, 2012 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, today announced that the Company was granted orphan drug status for folic acid solution for injection by the Europea...
Aug 28, 2012 WEST LAFAYETTE, Ind., Aug. 28, 2012 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, today announced that their company's management team will present at the following upcoming conferences: Bair...
Aug 14, 2012 WEST LAFAYETTE, Ind., Aug. 14, 2012 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, today announced that three posters will be presented by Endocyte scientists at the 244th American Chemical Society (A...
Aug 7, 2012 WEST LAFAYETTE, Ind., Aug. 7, 2012 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, today announced that Ron Ellis, president and CEO of Endocyte, will present at the Wedbush PacGrow Life Sciences Manag...
Aug 3, 2012 WEST LAFAYETTE, Ind., Aug. 3, 2012 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, today announced that Endocyte's approach of utilizing a SMDC targeted to the folate receptor (FR) may provide a promis...
Aug 2, 2012 Company Recognizes First Revenue From Merck Collaboration Conference Call Today at 4:30 EDT WEST LAFAYETTE, Ind., Aug. 2, 2012 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, today...
Aug 2, 2012 WEST LAFAYETTE, Ind., Aug. 2, 2012 (GLOBE NEWSWIRE) -- Endocyte, Inc., (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, today announced that the company has secured DOXIL® (doxorubicin HCl liposome injection) supply from Janssen Pro...
Jul 26, 2012 WEST LAFAYETTE, Ind., July 26, 2012 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, today announced the appointment of David Meek to the newly created position of chief commercial officer. Mr. Meek wil...
Jul 25, 2012 WEST LAFAYETTE, Ind., July 25, 2012 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, today announced Marc Kozin has joined the Endocyte board of directors. Mr. Kozin is currently a Senior Adviso...
Jul 25, 2012 WEST LAFAYETTE, Ind., July 25, 2012 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, today announced that the company will host a conference call on Thursday, Aug. 2, at 4:30 p.m. EDT, to discuss its se...
Jul 9, 2012 WEST LAFAYETTE, Ind., July 9, 2012 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, today announced Peter Meldrum, president and chief executive officer of Myriad Genetics, has joined the Endocyte board...
Jul 3, 2012 WEST LAFAYETTE, Ind., July 3, 2012 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, today announced that Mike Sherman, chief financial officer for Endocyte, will present at the JMP Securities 7th Annual...
May 31, 2012 WEST LAFAYETTE, Ind., May 31, 2012 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, today announced that Ron Ellis, president and CEO of Endocyte, will present at the upcoming Jefferies 2012 Global Heal...
May 10, 2012 WEST LAFAYETTE, Ind., May 10, 2012 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, today announced financial results for the first quarter ending March 31, 2012, and provided an operational update. ...
May 3, 2012 WEST LAFAYETTE, Ind., May 3, 2012 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, today announced that the company will host a conference call on Thursday, May 10, at 4:30 p.m. EDT to discuss its first...
Apr 20, 2012 WEST LAFAYETTE, Ind., April 20, 2012 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, today announced that previously reported data on vintafolide (EC145), Endocyte's lead drug candidate and etarfolatid...
Apr 16, 2012 WHITEHOUSE STATION N.J. & WEST LAFAYETTE, Ind.--(BUSINESS WIRE)-- Merck, known as MSD outside the United States and Canada, (NYSE: MRK) and Endocyte Inc. (NASDAQ: ECYT), today announced that they have entered into an agreement to develop and commercialize Endocyte's novel investigational therapeutic candidate vin...
Mar 26, 2012 WEST LAFAYETTE, Ind., March 26, 2012 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, today announced that three poster presentations will be presented by Endocyte scientists at the 2012 Annual Meeting ...
Mar 23, 2012 WEST LAFAYETTE, Ind., March 23, 2012 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, today announced that it will hold its 2012 Annual Meeting of Stockholders on Thurs., May 31, 2012, in Indianapolis. ...
Mar 22, 2012 -- Vintafolide for EC145 Therapeutic -- -- Etarfolatide for EC20 Companion Imaging Agent -- WEST LAFAYETTE, Ind., March 22, 2012 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, today announ...
Mar 13, 2012 - Expects to File Third Quarter of 2012 - - EC145 and EC20 Granted Orphan Drug Status by European Commission - - Updated Overall Survival Data Improved Compared to Interim Analysis - WEST LAFAYETTE, Ind., March 13, 2012 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small mo...
Mar 13, 2012 WEST LAFAYETTE, Ind., March 13, 2012 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, today announced financial results for the fourth quarter and year ending Dec. 31, 2011, and provided an operational ...
Mar 6, 2012 WEST LAFAYETTE, Ind., March 6, 2012 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, today announced that the company will host a conference call on Tuesday, March 13, at 4:30 p.m. EDT to discuss its fo...
Mar 5, 2012 WEST LAFAYETTE, Ind., March 5, 2012 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, today announced that the FDA has approved the importation of Endocyte's supply of Doxil® from Europe into the U....
Feb 27, 2012 WEST LAFAYETTE, Ind., Feb. 27, 2012 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, today announced that management will present at the upcoming Cowen and Company 32nd Annual Health Care Conference on ...
Feb 8, 2012 WEST LAFAYETTE, Ind., Feb. 8, 2012 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, today announced that their company's management team will present at the following upcoming investment conferences: ...
Dec 13, 2011 Analyses Confirm Greatest Benefit in FR(++) Population Conference Call/Webcast at 8:30 a.m. EST Today WEST LAFAYETTE, Ind., Dec. 13, 2011 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized th...
Nov 18, 2011 WEST LAFAYETTE, Ind., Nov. 18, 2011 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, today announced that it has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq:^NBI) as part of NAS...
Nov 10, 2011 WEST LAFAYETTE, Ind., Nov. 10, 2011 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates and companion imaging diagnostics for personalized therapy, today announced financial results for the third quarter ending September 30, 2011, and provided an operational update. ...
Nov 3, 2011 WEST LAFAYETTE, Ind., Nov. 3, 2011 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, today announced that the company will host a conference call on Thursday, November 10, 2011, at 4:30 PM Eastern Standa...
Oct 14, 2011 WEST LAFAYETTE, Ind., Oct. 14, 2011 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, today announced that Mike Sherman, chief financial officer of Endocyte, will present at the upcoming 18th Annual News...
Sep 8, 2011 WEST LAFAYETTE, Ind., Sept. 8, 2011 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, today announced that a poster about its EC-FV-04 study will be presented at the 17th International Meeting of the Eur...
Aug 31, 2011 WEST LAFAYETTE, Ind., Aug. 31, 2011 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, today announced that Ron Ellis, president and CEO of Endocyte, will be presenting at two upcoming investor conference...
Aug 23, 2011 WEST LAFAYETTE, Ind., Aug. 23, 2011 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, today announced that the company's proprietary design strategies for the synthesis of SMDCs will be outlined in six p...
Aug 11, 2011 -  EU Marketing Authorization Application Filing for EC145 and EC20 in Platinum-Resistant Ovarian Cancer Expected in the First Quarter of 2012 -  Phase 2 Trial of EC145 in Non-Small Cell Lung Cancer Expected to Initiate in the First Quarter of 2012 WEST LAFAYETTE, Ind., Aug. 11, 2011 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT),...
Aug 10, 2011 WEST LAFAYETTE, Ind., Aug. 10, 2011 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, today announced that Ron Ellis, President and CEO of Endocyte, will present at the upcoming 2011 Life Sciences Manage...
Aug 4, 2011 WEST LAFAYETTE, Ind., Aug. 4, 2011 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, today announced that the company will host a conference call on Thursday, August 11, 2011, at 4:30 PM Eastern Daylight...
Aug 3, 2011 WEST LAFAYETTE, Ind., Aug. 3, 2011 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, today announced that Mike Sherman, Chief Financial Officer of Endocyte, will present at the upcoming Canaccord Genuity...
Aug 2, 2011 WEST LAFAYETTE, Ind., Aug. 2, 2011 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, announced today the closing of the underwritten public offering of 6,681,420 shares of its common stock at $12.26 per ...
Jul 27, 2011 WEST LAFAYETTE, Ind., July 27, 2011 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, announced today the pricing of the underwritten public offering of 5,809,931 shares of its common stock at a price to...
Jul 14, 2011 WEST LAFAYETTE, Ind., July 14, 2011 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commissi...
Jun 15, 2011 WEST LAFAYETTE, Ind., June 15, 2011 (GLOBE NEWSWIRE) -- Endocyte, Inc., (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, today announced the appointment of Binh Nguyen, M.D., Ph.D. as Vice President of Clinical Affairs. He succeeds Richa...
Jun 5, 2011 -      Data Presented at 2011 ASCO Annual Meeting -      260 Percent (4.0 Month) Increase in Median Progression-Free Survival in Folate Receptor Positive Patient Subgroup -      Plan to File for Conditional Approval in Europe -      Initiated Phase 3 PROCEED Trial WEST LAFAYETTE, Ind., June 5, 2011 (GLOBE NEWSWIRE) -...
Jun 1, 2011 WEST LAFAYETTE, Ind., June 1, 2011 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, announced today that Ron Ellis, President and CEO of Endocyte, will present at the upcoming Jefferies 2011 Global Heal...
May 19, 2011 WEST LAFAYETTE, Ind., May 19, 2011 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, announced today that the final progression free survival (PFS) data from the Phase 2 PRECEDENT clinical trial of EC145...
May 5, 2011 WEST LAFAYETTE, Ind., May 5, 2011 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, today reported financial results for the first quarter ended March 31, 2011, and provided an operational update. ...
Apr 28, 2011 WEST LAFAYETTE, Ind., April 28, 2011 (GLOBE NEWSWIRE) -- Endocyte, Inc., (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, announced today that the company will host a conference call on Thursday, May 5, 2011, at 4:30 PM Eastern Daylight ...
Apr 26, 2011 WEST LAFAYETTE, Ind., April 26, 2011 (GLOBE NEWSWIRE) -- Endocyte, Inc., (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, today announced its plan to prepare two marketing authorization applications to the European Medicines Agency (EMA)...
Apr 8, 2011 WEST LAFAYETTE, Ind., April 8, 2011 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapies for the treatment of cancer and inflammatory diseases, announced today that Mike Sherman, chief financial officer of Endocyte, will present at the upcoming BioCentury Future Leaders in the Biotech Industry ...
Apr 1, 2011 WEST LAFAYETTE, Ind., April 1, 2011 (GLOBE NEWSWIRE) -- Endocyte, Inc., (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates and companion imaging diagnostics for personalized therapy, announced today that three poster presentations will be presented by Endocyte scientists at the 102nd Annual Meeting of the ...
Apr 1, 2011 WEST LAFAYETTE, Ind., April 1, 2011 (GLOBE NEWSWIRE) -- Endocyte, Inc., (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapies for the treatment of cancer and inflammatory diseases, announced today that the company has been added to the Russell 2000® Index, as part of Russell's quarterly IPO additions that took place on March...
Mar 31, 2011 WEST LAFAYETTE, Ind., March 31, 2011 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapies for the treatment of cancer and inflammatory diseases, announced today that Ron Ellis, president and CEO of Endocyte, will present at the upcoming Leerink Swann Cancer Roundtable Conference on Thursday, Ap...
Mar 25, 2011 WEST LAFAYETTE, Ind., March 25, 2011 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapies for the treatment of cancer and inflammatory diseases, announced today that it will hold its 2011 Annual Meeting of Stockholders on Thursday, May 26, 2011, in Indianapolis, Indiana.  The record dat...
Mar 10, 2011 WEST LAFAYETTE, Ind., March 10, 2011 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapies for the treatment of cancer and inflammatory diseases, today reported consolidated 2010 financial results and reviewed 2010 development highlights. "Endocyte made significant progress in demonstrat...
Mar 4, 2011 WEST LAFAYETTE, Ind., March 4, 2011 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapies for the treatment of cancer and inflammatory diseases, announced today that the company will host a conference call for investors and analysts on Thursday, March 10, 2011 at 4:30 PM Eastern Standard Time to...
Feb 9, 2011 WEST LAFAYETTE, IN, February 9, 2011 – Endocyte, Inc., (NASDAQ:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates and companion imaging diagnostics for personalized therapy, announced today the closing of its initial public offering of 14,375,000 shares of common stock (including 1,875,000 shares of common s...
Feb 4, 2011
Aug 30, 2010
PDF
Add to Briefcase
Aug 17, 2010
PDF
Add to Briefcase
Jun 5, 2010
PDF
Add to Briefcase
May 11, 2010
PDF
Add to Briefcase
Mar 3, 2010
PDF
Add to Briefcase
Oct 27, 2009
PDF
Add to Briefcase
Oct 21, 2009
PDF
Add to Briefcase
Oct 15, 2009
PDF
Add to Briefcase
Aug 26, 2009
PDF
Add to Briefcase
Aug 10, 2009
PDF
Add to Briefcase
Jul 14, 2009
PDF
Add to Briefcase
May 5, 2009
PDF
Add to Briefcase
Apr 17, 2009
PDF
Add to Briefcase
Mar 24, 2009
PDF
Add to Briefcase
Feb 19, 2009
PDF
Add to Briefcase
Oct 13, 2008
PDF
Add to Briefcase
Sep 10, 2008
PDF
Add to Briefcase
Jan 25, 2008
PDF
Add to Briefcase
Jan 4, 2008
PDF
Add to Briefcase
Jan 3, 2008
PDF
Add to Briefcase
Dec 21, 2007
PDF
Add to Briefcase
Dec 17, 2007
PDF
Add to Briefcase
Mar 23, 2007
PDF
Add to Briefcase
Nov 29, 2006
PDF
Add to Briefcase
Oct 11, 2006
PDF
Add to Briefcase
Oct 9, 2006
PDF
Add to Briefcase
Sep 12, 2006
PDF
Add to Briefcase
May 16, 2006
PDF
Add to Briefcase
Apr 20, 2006
PDF
Add to Briefcase
Jan 5, 2006
PDF
Add to Briefcase
Nov 2, 2005
PDF
Add to Briefcase
Jul 13, 2005
PDF
Add to Briefcase
Apr 26, 2005
PDF
Add to Briefcase
Mar 30, 2005
PDF
Add to Briefcase
Dec 6, 2004
PDF
Add to Briefcase
Nov 15, 2004
PDF
Add to Briefcase
Aug 15, 2004
PDF
Add to Briefcase
May 10, 2004
PDF
Add to Briefcase
Apr 1, 2004
PDF
Add to Briefcase
Nov 19, 2003
PDF
Add to Briefcase
Oct 16, 2003
PDF
Add to Briefcase
Sep 5, 2003
PDF
Add to Briefcase
Aug 15, 2003
PDF
Add to Briefcase
May 9, 2003
PDF
Add to Briefcase
May 6, 2003
PDF
Add to Briefcase
Jan 31, 2003
PDF
Add to Briefcase
Oct 1, 2002
PDF
Add to Briefcase
Jun 19, 2002
PDF
Add to Briefcase
May 14, 2002
PDF
Add to Briefcase
Oct 1, 2001
PDF
Add to Briefcase
Jul 10, 2001
PDF
Add to Briefcase
Feb 22, 2001
PDF
Add to Briefcase
Mar 1, 1999
PDF
Add to Briefcase
Page:
1
Add to Briefcase = add release to Briefcase